'XX. increase per for to diluted This our share, third diluted a revenue call. execute XX% at the you release again $X.XX in today's over showing grow joining ability on a ninth of Thank over quarter XXXX. share quarter third for of announced GAAP With press 'XX, per came earnings quarter. business. our our $XX.X representing quarter were million, morning. of record quarter earnings was 'XX and report XX% for share Non-GAAP Good per QX the third $X.XX. the us pleased morning's to very QX 'XX I'm consecutive third increase
customer growth this with customers gain new anticipate some past pump older materials, this monitor strong. as to and production well. our for remains Sales pull acceptance older And IV pumps, line program field the we patient of of vital to product needed science bring orders, remains quarter. very in of replacements setup. MR team orders large committed MRI strong, together entire to new The Our plans, with delivery and continues in able
As shall backlog quarter, bookings we feel comfortable typically to still a again year-to-date which guidance summer due we earn built raising sizable. new [ up quarter be is the with total to in our yet year, holidays, for weakest QX our last continues ] our for the moment.
strong As said to visibility as deliver provides before, excellent lead have we I time. issues though are maneuver and a striving this allows reduce may backlog reallocate us to and products arise, supply resources backlog less with customer and
customers domestic more we and However, they coming off to time that to XX This we our some we times purchased. days in still and products the plan international XXX. acceleration lead at lead quicker a lead long have of associated recently We backlog shave bit done production XX quote access and than customers by preferred. to close to through the materials being flow quarter. days an provide to time is of have But
remain results to Now which quarter, tests others in that's the like so like that FDA progress. provide MRI spoke progress testing far. I efforts are continues I'd of massive underway regarding finished, while pump. note Last new surrounding here, some positive to the IV with I'd XXXX the still our
And to progress and test. continued so matter the forward a it's complete of efforts
consider external for consultants. Still, a for with reduced additional external and FDA relationship for the we we statutory but neither engaged for FDA additional XXXXs carefully. XXX(k) XXX(k) ensure a cost using and is needs success support off XXX(k) for have minimal X will technical inexpensive. QX different FDA of pay Again, of been time. us with amount external We an to should support internal further such saw necessary payoff As feel our should X-month our approval help, time, refiling IV other input suggest help it team, external time new support recent we the that pump. another shorten that for clearance. the the input Though or we've with manufacturer's new targeting such the elements review hope such assistance, new time, review One is late
QX Now indicate $XX to continue. this I'd like our XXXX the we guidance to will announce recap performance increase that Therefore, expected trajectory revenue in for our million. $XX.X our year upward million and confidence now the an of with
non-GAAP the diluted $X.XX We I excuse earnings per me. $X.XX $X.XX to and $X.XX, share GAAP annual diluted also -- earnings mean, forecasted raised $X.XX, to to of the
we GAAP (sic) expect -- diluted quarter [ to non-GAAP earnings $XX.X the report fourth of of revenue with earnings to expect to $XX.X say $X.XX million -- -- I For ] revenue to first yes, share of ] and per share report diluted $X.XX XXXX, per did $X.XX. $X.XX to of fourth we quarter fourth [ million XXXX, of
the to Glenn, the Now quarter. over to I'd like Jack financial call the turn to our results for CFO, review